Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Kreitman Website

Robert J. Kreitman, M.D.

Selected Publications

1)  Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I.
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
N. Engl. J. Med. 345: 241-7, 2001.
[Journal]
2)  Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I.
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.
J. Clin. Oncol. 27: 2983-90, 2009.
[Journal]
3)  Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ.
VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.
Blood. 114: 4687-95, 2009.
[Journal]
4)  Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I.
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia.
J. Clin. Oncol. 30: 1822-8, 2012.
[Journal]
5)  Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ.
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.
Blood. 119: 3330-2, 2012.
[Journal]
6)  Arons E, Adams S, Venzon DJ, Pastan I, Kreitman RJ.
Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.
Br. J. Haematol. [Epub ahead of print], 2014.
[Journal]
7)  Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS.
High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.
Nat. Genet. 46: 8-10, 2014.
[Journal]
8)  Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I.
Immunotoxins for leukemia.
Blood. 123: 2470-7, 2014.
[Journal]
9)  Mazor R, Eberle JA, Hu X, Vassall AN, Onda M, Beers R, Lee EC, Kreitman RJ, Lee B, Baker D, King C, Hassan R, Benhar I, Pastan I.
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.
Proc. Natl. Acad. Sci. U.S.A. 111: 8571-6, 2014.
[Journal]
10)  Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA.
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
Br. J. Haematol. [Epub ahead of print], 2014.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 6/20/2014.